• Home
  • PR



게시물 상세
Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD
Date : 2019-03-18     View : 2766

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

Mar. 18, 2019

- License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration.

- OliX to receive an upfront payment of 2 million euro, and eligible to receive milestones, plus royalty for the development and commercialization in Europe, Middle East and Africa.

- OliX continues to hold the rights of OLX301A program for US and Asia.

OliX Pharmaceuticals, Inc. (Kosdaq: 226950), a leading developer of RNAi therapeutics, announced 

today that it has signed a license and collaboration agreement with Théa Open Innovation, a sister company of Laboratoires Théa S.A.S (“Théa”) ,the leading independent pharmaceutical company in Europe dedicated to ophthalmology, to develop and commercialize OLX301A. 

Under the agreement, OliX receives a non-refundable and non-creditable upfront payment of 2 million euro and is eligible to receive milestone payments upon achievement of clinical milestones, plus royalty for the development and commercialization. 

Dong-ki Lee, the founder and CEO of OliX, stated, “OliX’s cp-asiRNA platform technology is an RNAi platform optimal for the development of ocular therapeutics, which can circumvent potential side effects arising from the existing siRNA technology. The collaboration with Théa proves that OliX’s ophthalmology RNAi platform has been recognized in global pharmaceutical market, and we will continue to expand pipelines for eye diseases.”

For Jean-Frédéric CHIBRET, Chairman of Théa Group, “this program aims to enlarge Théa’s ophthalmology development portfolio in retinal vascular pathologies. Thanks to this partnership, patients will be offered a new alternative to treat posterior segment eye diseases, in addition to the current existing medications».

Théa has been granted licensing rights for OLX301A program in EU countries, Middle East and Africa. OliX continues to hold the rights of OLX301A program for US and Asia.

Age-related macular degeneration diagnosed as either dry or wet is deterioration of the retina and deeper layers of the eye that can lead to a loss of eye sight. While effective therapies for wet AMD exist, the treatment burden may lead to less than optimal vision outcomes for many patients over time and no cure for dry AMD has been developed yet. OliX’s OLX301A program is a first in class treatment which cure both wet and dry AMD and is expected to be registered for FDA approval of IND for phase 1 clinical trial.

About Age-Related Macular degeneration (AMD)

· Occurs when the small central portion of the retina, known as the macula, deteriorates

· The leading cause of severe vision loss in people over age 60 in developed countries

· Two types: wet AMD (10%) & dry AMD (90%)

· In USA, 175 million patients affected by AMD in 2014 (Source: All about vision, Understanding AMD 2014)

· Global wet AMD market: $ 7.65B in 2015 

· By 2025, expected dry AMD market: $ 6.58B (Source: Visiongain 2016)

· 98% of wet AMD patients were reported the onset of dry AMD in seven years

(Source: Ophthalmology. 2012 Jul;119(7):1388-98., Ophthalmology. 2013 Nov;120(11):2292-9)

→ Unmet medical needs for the development of a drug that can treat both wet and dry AMD exist

· Expected to grow to approx. about 11.6 B by 2026 

(Source: Global Data 2018, 7 major countries)

Théa Open Innovation by Laboratoires Théa S.A.S


Learn more: https://www.laboratoires-thea.com/en

OliX Pharmaceuticals, Inc.

OliX is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The company is currently developing novel therapeutic programs for treatment of various diseases with high unmet medical needs, including hypertrophic scar, dry & wet age-related macular degeneration (AMD), subretinal fibrosis, and idiopathic pulmonary fibrosis (IPF).

Learn more: http://www.olixpharma.com/main/main.php

Source by OliX Pharmaceuticals, Inc.

Prev OliX Pharmaceuticals Announces Harvard retina specialist Demetrios G. Vavvas, M.D., Ph.D., to join S
Next OliX Announces Clinical Candidate Nomination for the Treatment of Geographic Atrophy.